Press Releases

Date	Title	PDF Version
Dec 09, 2006	Eculizumab is Well Tolerated and Demonstrates Significant Improvement During 52 Weeks of Treatment in Open-Label Phase III SHEPHERD Study in PNH Patients
Dec 08, 2006	Alexion Pharmaceuticals Soliris(TM) (Eculizumab) data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting
Nov 29, 2006	Alexion to Present at BMO Capital Markets Focus on Healthcare Conference
Nov 22, 2006	Alexion To Present At Piper Jaffray 18th Annual Health Care Conference
Nov 21, 2006	Alexion Pharmaceuticals Announces Closing of Public Offering of Stock
Nov 14, 2006	FDA Grants Priority Review for Soliris(TM) (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Nov 14, 2006	Alexion Pharmaceuticals Announces Proposed Public Offering of Common Stock
Nov 10, 2006	Alexion to Present at the 2006 Credit Suisse Healthcare Conference
Nov 09, 2006	Alexion Pharmaceuticals Soliris(TM) (Eculizumab) Data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting
Nov 03, 2006	Alexion to Present At Cowen and Company 7th Annual Global Health Care Conference

Search